Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 11/20 | 0.44 |
| ▸ | CTSL | P07711 | 7/20 | 0.41 |
| ▸ | CTSB | P07858 | 7/20 | 0.41 |
| ▸ | CTSH | P09668 | 4/20 | 0.41 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | PADI1 | Q9ULC6 | 1/20 | 0.39 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GRN | P28799 | 1/20 | 0.38 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19088561 | 0.91 | CNR2 (0.40) | CTSKCTSLCTSBCTSHCTSS | |
| SCHEMBL18435573 | 0.84 | CTSK (0.47) | CTSKCTSLCTSBCTSHCTSS | |
| SCHEMBL23513830 | 0.84 | CTSK (0.47) | CTSKCTSLCTSBCTSHCTSS | |
| SCHEMBL31252283 | 0.84 | CTSK (0.40) | CTSKCTSLCTSBCTSHCTSS | |
| SCHEMBL25523633 | 0.83 | CTSK (0.45) | CTSKCTSLCTSBCTSHCTSS | |
| SCHEMBL23052492 | 0.83 | REN (0.44) | CTSKCTSLCTSBCTSHCTSS | |
| SCHEMBL24690943 | 0.83 | CTSK (0.42) | CTSKCTSLCTSBCTSHCTSS | |
| SCHEMBL805198 | 0.81 | GRN (0.50) | CTSKCTSLCTSBCTSSGRN | |
| SCHEMBL7566961 | 0.81 | GRN (0.50) | CTSKCTSLCTSBCTSSGRN | |
| SCHEMBL8310083 | 0.81 | CTSK (0.43) | CTSKCTSLCTSBCTSHCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210179580-A1 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PD1/PD-L1 ACTIVATION | Jubilant Prodel LLC | 2021-06-17 | — | — | US | disclosed |
| WO-2015058868-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | PANGAEA BIOTECH, S.L. (ES) | 2015-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179580-A1 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PD1/PD-L1 ACTIVATION | PDCD1, CD274, PDCD1LG2 | CTSK 2427/4885CTSL 887/4885CTSB 1930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.